Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.37 |
| ▸ | HINT1 | P49773 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 2/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | EIF4E | P06730 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261240 | 0.89 | CYP3A4 (0.38) | CYP3A4CYP2C9BTN3A1HINT1 | |
| SCHEMBL12261217 | 0.89 | CYP3A4 (0.38) | CYP3A4CYP2C9HINT1EIF4E | |
| SCHEMBL12261205 | 0.88 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1HINT1EIF4E | |
| SCHEMBL12260844 | 0.81 | CYP3A4 (0.41) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL14393214 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP2C9BTN3A1HINT1TYMS | |
| SCHEMBL14367303 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP2C9BTN3A1HINT1TYMS | |
| SCHEMBL12261233 | 0.79 | HPRT1 (0.41) | HINT1TAS1R3TAS1R1EIF4E | |
| SCHEMBL12253923 | 0.79 | CYP3A4 (0.46) | CYP3A4CYP2C9BTN3A1HINT1TYMS | |
| SCHEMBL12651147 | 0.79 | CYP3A4 (0.51) | CYP3A4CYP2C9HINT1TAS1R3TAS1R1 | |
| SCHEMBL14216817 | 0.79 | CYP3A4 (0.51) | CYP3A4CYP2C9HINT1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | CYP3A4 1378/4885CYP2C9 2679/4885BTN3A1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.